The purpose of this study is to evaluate a new treatment routine for patients with metastatic HER2 -positive breast cancer. We want to find out what effects, good and bad, using a Poly (ADP-Ribose) polymerase (PARP) inhibitor called niraparib in combination with trastuzumab has on patients with metastatic HER2- positive breast cancer.

Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

Metabolism is the process your body uses to make energy. The main purpose of this study is to observe the impact of metabolic processes on cognition and behavior.

In this study, we want to interview women with pregnancy Medicaid in North Carolina. We would like to learn what would help more people go to the dentist and get dental care during this time. That way, we can make suggestions for policy changes to help more people get the care they need.

Current practice in military blood transfusion is to use specific IV bags and chemical preservatives to transfer blood from the donor to the injured recipient. Our goal is to study if this blood transfusion can occur using a basic syringe without any preservative. This will help military personnel in areas will limited resources to provide blood transfusions to injured soldiers and save lives. We will also be evaluating ultrasound techniques which determine if a patient needs fluid (either regular IV fluid or blood transfusion).

Participants are asked to come into the lab for a 1.5-hour session. During this session they will complete questionnaires and tasks. Questionnaires will ask about physical and mental health, life experiences, emotions, and cognitive associations. Tasks are designed to measure participants' sensitivity to heartbeat and stomach sensations, as well as socioemotional functioning.

Fuel for Thought: How do sugar and fat affect each other in the brain? Do you ever wonder what happens in your brain when you eat dessert? And why sugary and fatty foods are so appealing? If so, you may eligible to participate in a research study to understand the impact of sugar and fat on the brain!

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

In this study, we want to learn if decreasing or increasing your radiation and hormonal therapy has an effect on high risk prostate cancer.